Sandoz launches US authorised generic of Miacalcin nasal spray
This article was originally published in Scrip
Executive Summary
Sandoz (Novartis) has launched in the US calcitonin-salmon nasal spray, an authorised generic version of the branded product Miacalcin, which is marketed by Novartis. In November 2008, the US FDAgranted final approval to Apotex's ANDA for a calcitonin-salmon nasal spray, and as first filer, Apotex has been granted 180 days of exclusivity. In December 2008, the FDA granted tentative approval to MDRNA (formerly Nastech Pharmaceutical) for its ANDA for the product; full approval is expected to follow after the completion of Apotex's exclusivity period (June 2009). In a statement, MDRNA said that in December 2003, the FDA accepted for filing its 505(j) paragraph four ANDAs for the product, and in October 2004, it entered into an exclusive licence and supply agreement with Par Pharmaceutical for US distribution and marketing. MDRNA is responsible for obtaining regulatory approval and manufacturing. Recently, Apotex was prohibited from marketing a generic version of Unigene's nasal calcitonin product, Fortical (calcitonin salmon rDNA origin), prior to a court ruling (Scrip Online, December 9th, 2008).
You may also be interested in...
ChemoCentryx cuts price to get $45M IPO away
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio raises $16.9M as it advances PhIII premature ejaculation drug
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Money talks: Verastem leverages IPO to build cancer stem cell pipeline
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.